Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
2.130
-0.090 (-4.05%)
At close: Dec 5, 2025, 4:00 PM EST
2.240
+0.110 (5.16%)
After-hours: Dec 5, 2025, 7:47 PM EST
Senti Biosciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Senti Biosciences stock have an average target of 8.75, with a low estimate of 5.00 and a high estimate of 12. The average target predicts an increase of 310.80% from the current stock price of 2.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Senti Biosciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $6 | Buy | Initiates | $6 | +181.69% | Nov 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +463.38% | Oct 14, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +463.38% | Aug 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +463.38% | Jun 12, 2025 |
| Laidlaw & Co. | Laidlaw & Co. | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +134.74% | Jun 6, 2025 |
Financial Forecast
Revenue This Year
680.00K
Revenue Next Year
1.70M
from 680.00K
Increased by 150.00%
EPS This Year
-2.77
from -12.03
EPS Next Year
-1.44
from -2.77
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.1M | 5.3M | ||||
| Avg | 680,003 | 1.7M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 672.1% | ||||
| Avg | - | 150.0% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.43 | -0.93 | ||||
| Avg | -2.77 | -1.44 | ||||
| Low | -2.84 | -1.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.